Swiss pharmaceutical group Roche has announced plans to invest SFr1.3 billion ($1.25 billion) on production, research and administration sites in its home market.
The company will spend SFr550 million on a new office tower at its headquarters in Basel, which will be the tallest building in Switzerland. It will be 154 metres high when completed and home to 2,400 employees, including 1,700 currently scattered across other sites.
Roche will invest another SFr250 million on a building for research and development in the city.
The firm will put SFr300 million into its production and development facilities in Kaiseraugst, canton Aargau. Roche also plans an outlay of SFr200 million in Rotkreuz, canton Zug, where much of its diagnostics activities are concentrated.
Roche says it has created 1,000 jobs in Switzerland in the past three years. It currently employs 9,500 people in the country, with more than a quarter involved in research and development activities.
In compliance with the JTI standards